Eosinophil sequestration and activation are associated with the onset and severity of systemic adverse reactions following the treatment of onchocerciasis with ivermectin

Journal of Infectious Diseases

Volumn 179, Issue 3, 1999, Pages 738-742

  Cooper, Philip J ^a,b,c,d,e   Awadzi, Kwablah ^a,b,c,d   Ottesen, Eric A ^a,b,c,d   Remick, Daniel ^a,b,c,d   Nutman, Thomas B ^a,b,c,d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Hohoe Hospital   (Ghana)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 5; IVERMECTIN; NEUROTOXIN; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DEGRANULATION; DRUG MEGADOSE; EOSINOPHIL; GHANA; HUMAN; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; MALE; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGRANULOCYTOSIS; ANIMALS; ANTHELMINTICS; CELL DEGRANULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EOSINOPHILS; GHANA; HUMANS; INTERLEUKIN-5; IVERMECTIN; MALE; ONCHOCERCA VOLVULUS; ONCHOCERCIASIS; PLACEBOS;

EID: 0033400276     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314647     Document Type: Article

References (14)

1. 1. Awadzi K, Opoku NO, Addy ET, Quartey BT. The chemotherapy of onchocerciasis. XIX. The clinical and laboratory tolerance of high dose ivermectin. Trop Med Parasitol 1995;46:131-7.
2. 2. Francis H, Awadzi K, Ottesen EA. The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity. Am J Trop Med Hyg 1985;34:529-36.
3. 3. Cooper PJ, Guderian RH, Prakash D, et al. RANTES in onchocerciasis: changes with ivermectin treatment. Clin Exp Immunol 1996;106:462-7.
4. 4. Ackerman SJ, Kephart GM, Francis H, Awadzi K, Gleich GJ, Ottesen EA. Eosinophil degranulation: an immunologic determinant in the pathogenesis of the Mazzotti reaction in human onchocerciasis. J Immunol 1990;144:3961-9.
5. 5. Wildenburg G, Darge K, Knab J, Tischendorf FW, Bonow I, Buttner DW. Lymph nodes of onchocerciasis patients after treatment with ivermectin: reaction of eosinophil granulocytes and their cationic granule proteins. Trop Med Parasitol 1994;45:87-96.
6. 6. Kita H, Gleich GJ. Chemokines active on cosinophils: potential roles in allergic inflammation. J Exp Med 1996;183:2421-6.
7. 7. Wang J, Palmer K, Lotrall J, et al. Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. J Clin Invest 1998;102:1132-41.
8. 8. Venge P, Dahl D, Fredens K, Hallgren R, Peterson C. Eosinophil cationic proteins ECP and EPX in health and disease. In: Yoshida T, Torisu M, eds. Immunobiology of the eosinophil. New York: Elsevier, 1983:163-9.
9. 9. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophil activation in asthma. N Engl J Med 1990;323:1033-9.
10. 10. Cooper PJ, Espinel I, Paredes W, Guderian RH, Nutman TB. Impaired tetanus-specific cellular and humoral responses following tetanus vaccination in human onchocerciasis: a possible role for IL-10. J Infect Dis 1998;178:1133-8.
11. 11. Guderian RH, Anselmi M, Espinel M, Mancero T, Rivadeneira G, Cooper PJ. Successful control of onchocerciasis with ivermectin in Ecuador. Trop Med Int Health 1997;2:982-8.
12. 12. Greene BM, Taylor HR, Aikawa M. Cellular killing of microfilariae of Onchocerea volvulus: eosinophil and neutrophil-mediated immune serum-dependent destruction. J Immunol 1981;127:1611-8.
13. 13. Tischendorf FW, Brattig NW, Hoyer A, Medina-delaGarza, Geisinger F. Modulatory effects of antifilarial drugs ivermectin, CGP 6140 and CGP 20376 on the oxidative burst of eosinophilic granulocytes. Acta Trop 1993;53:27-37.
14. 14. Kephart GM, Gleich GJ, Connor DH, Gibson DW, Ackerman SJ. Deposition of eosinophil granule major basic protein onto microfilariae of Onchocerea volvulus in the skin of patients treated with diethylcarbamazine. Lab Invest 1984;50:51-61.